Translational Basic and Clinical Research Training in Rheumatology

风湿病学转化基础和临床研究培训

• 批准号: 10411569
• 负责人: Jill P Buyon
• 金额: $ 31.08万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-05-01 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10411569
• 关键词: Basic Science; Clinical Research; Research Training; Rheumatology

The Translational Basic and Clinical Research Training in Rheumatology, led in its first cycle by NYU Rheumatology Division Director Dr. Jill Buyon, will in its second cycle be co-directed under an mPI arrangement. Adding to Dr. Buyon’s extensive translational experience in SLE and autoimmunity, Dr. Jose Scher provides complementary expertise in inflammatory arthridities, including psoriatic and rheumatoid arthritis. Our mission remains clear: to support trainees through an extended period of development; to leverage emerging research opportunities to engage and excite physicians; and to bring clinical context to the pre-doctoral bench. Accordingly, our program extends traditional ACGME training and again proposes support for 2-yr training of 3 fellowship graduates, plus 1 predoctoral MD/PhD candidate to establish an early pipeline to rheumatology. In our first 4 years: a) 3 rheumatology graduates completed training (2 advancing to NYU faculty positions with external multi-year grants and publications, and 1 garnering a leadership role in industry based on accomplishments; b) 2 pre-doctoral MD/PhD trainees successfully defended a PhD thesis with publications; c) 3 fellows and 1 MD/PhD candidate (URM) remain in training; d) 2 NYU junior faculty advanced as Primary Mentors with new R01 awards e) Dr. Timothy Niewold, expertise in type I Interferon, was recruited; f) new NIH research programs were added, including a P50 in preclinical and clinical lupus, and renal and skin transcriptomics in SLE as part of AMP; g) clinical/basic research programs addressing COVID-19 and rheumatic diseases spawned during the pandemic engaged the pivot of trainees and faculty as they assumed unprecedented patient responsibilities. At the core of the present proposal is interdisciplinary training along 2 methodologically distinct research tracks, each bearing the prefix “translational” –basic or clinical – to emphasize the common purpose of all healthcare investigators. An Early Scientist Pathway is again offered to MD/PhD candidates recruited through our school’s MD/PhD and graduate programs, including the Immunology/Inflammation program and the newly established Translational Research Immunology Center (TrIC). Training tracks are grounded in core disease clusters reflecting faculty expertise and nationally recognized leadership: 1) lupus and diseases of systemic autoimmunity; 2) inflammatory and autoimmune arthritis; and 3) degenerative and metabolic bone disease. Each incorporates common and customized didactics; individualized research training experiences with teams of Primary, Associate, and Methodological Mentors to integrate science and medicine; a hand-picked Advisory Mentoring Committee for each trainee; and planning to support post-T32 faculty advancement. Programmatic success is evaluated though Executive Committee meetings and an Annual Showcase Retreat. Strong institutional commitment supports infrastructure and additional funding. The twice-renewed Clinical/Translational Science Institute provides extensive resources. This T32 program represents the ongoing trajectory of our capacity-building and scientific dedication, affirming and expanding commitment to advanced training in the rheumatic diseases.

风湿病学转化基础和临床研究培训，第一期由纽约大学牵头 风湿病科主任 Jill Buyon 博士将在第二个周期中根据 mPI 安排共同指导。 除了 Buyon 博士在 SLE 和自身免疫方面丰富的转化经验之外，Jose Scher 博士还提供了 炎症性关节炎（包括银屑病和类风湿性关节炎）方面的补充专业知识。我们的使命 仍然很明确：支持受训者的长期发展；利用新兴研究 吸引和激励医生的机会；并将临床背景带入博士前工作台。 因此，我们的计划扩展了传统的 ACGME 培训，并再次建议支持 3 人的 2 年培训 奖学金毕业生，加上一名博士前医学博士/博士候选人，以建立风湿病学的早期管道。在我们的 前 4 年：a) 3 名风湿病学毕业生完成了培训（其中 2 名毕业生通过外部晋升到纽约大学教职） 多年赠款和出版物，以及 1 基于成就获得行业领导地位； b) 2名博士前MD/PhD学员成功通过论文答辩并发表论文； c) 3 名研究员和 1 名医学博士/博士 候选人（URM）继续接受培训； d) 2 名纽约大学初级教师晋升为主要导师并获得新的 R01 奖项 e) 聘请I型干扰素领域专家Timothy Niewold博士； f) 增加了新的 NIH 研究项目， 包括临床前和临床狼疮中的 P50，以及作为 AMP 一部分的 SLE 中的肾脏和皮肤转录组学；克） 针对大流行期间产生的 COVID-19 和风湿性疾病的临床/基础研究项目 当学员和教职员工承担起前所未有的患者责任时，他们就成为了中心。其核心是 目前的建议是沿着两个方法论不同的研究方向进行跨学科培训，每个方向都有 前缀“翻译”（基础或临床），以强调所有医疗保健调查人员的共同目标。早期的 再次向通过我校MD/PhD和研究生招募的MD/PhD候选人提供科学家衔接课程 计划，包括免疫学/炎症计划和新建立的转化研究 免疫学中心（TrIC）。培训课程以核心疾病群为基础，反映教师的专业知识和 全国公认的领导地位：1）狼疮和系统性自身免疫性疾病； 2）炎症和 自身免疫性关节炎； 3）退行性和代谢性骨病。每个都包含常见的和 定制教学法；与初级、副职和高级团队的个性化研究培训经验 整合科学与医学的方法论导师；每个项目都有一个精心挑选的咨询指导委员会 学员;并计划支持 T32 后教师的晋升。计划的成功是经过评估的 执行委员会会议和年度展示静修会。强有力的机构承诺支持 基础设施和额外资金。两次更新的临床/转化科学研究所提供广泛的 资源。这个 T32 计划代表了我们能力建设和科学奉献的持续轨迹， 肯定并扩大对风湿病高级培训的承诺。